Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | ITGAL | P20701 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | CRHBP | P24387 | 2/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29447258 | 1.00 | ABCG2 (0.33) | ABCG2ITGB2ICAM1ITGALADRA2A | |
| SCHEMBL9833025 | 0.88 | ABCG2 (0.42) | ABCG2ITGB2ICAM1ITGALADRA2A | |
| SCHEMBL29447257 | 0.88 | ABCG2 (0.42) | ABCG2ITGB2ICAM1ITGALADRA2A | |
| SCHEMBL29447260 | 0.88 | ABCG2 (0.42) | ABCG2ITGB2ICAM1ITGALADRA2A | |
| SCHEMBL29447261 | 0.88 | ABCG2 (0.42) | ABCG2ITGB2ICAM1ITGALADRA2A | |
| SCHEMBL3075319 | 0.68 | — | — | |
| SCHEMBL30587754 | 0.68 | ITGB2 (0.65) | ABCG2ITGB2ICAM1ITGALMAPT | |
| SCHEMBL30313796 | 0.68 | — | — | |
| SCHEMBL24735666 | 0.67 | ABCG2 (0.39) | ABCG2ITGB2ICAM1ITGALLMNA | |
| SCHEMBL10821693 | 0.67 | ABCG2 (0.39) | ABCG2ITGB2ICAM1ITGALLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3730502-B1 | SYNTHESIS AND APPLICATION OF OXASPIROCYCLODIPHOSPHINE LIGAND | SHENZHEN CATALYS TECH CO LTD (CN) | 2024-10-02 | — | — | EP | disclosed |
| US-12071444-B2 | Synthesis and use of oxa-spirodiphosphine ligand | SHENZHEN CATALYS TECHNOLOGY CO., LTD (CN) | 2024-08-27 | — | — | US | disclosed |
| US-20220185835-A1 | SYNTHESIS AND USE OF OXA-SPIRODIPHOSPHINE LIGAND | SHENZHEN CATALYS TECHNOLOGY CO., LTD (CN) | 2022-06-16 | — | — | US | disclosed |
| US-11299507-B2 | Synthesis and use of oxa-spirodiphosphine ligand | SHENZHEN CATALYS TECHNOLOGY CO., LTD. (CN) | 2022-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185835-A1 | SYNTHESIS AND USE OF OXA-SPIRODIPHOSPHINE LIGAND | OXER1, OXGR1, ICOSLG | ABCG2 1022/4885ITGB2 968/4885ICAM1 2140/4885 |
| US-12071444-B2 | Synthesis and use of oxa-spirodiphosphine ligand | OXER1, OXGR1, ICOSLG | ABCG2 1022/4885ITGB2 968/4885ICAM1 2140/4885 |
| US-11299507-B2 | Synthesis and use of oxa-spirodiphosphine ligand | OXER1, OXGR1, FOXO1 | ABCG2 953/4885ITGB2 750/4885ICAM1 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.